Novavax, Inc. and Pfizer, Inc. have signed a licensing arrangement allowing Pfizer access to Novavax’s Matrix-M adjuvant technology to boost immune response to vaccines. The agreement will allow for use in vaccines targeting up to two infectious diseases.1
Novavax’s Matrix-M technology is an aluminum-free adjuvant designed to enhance the immune response in protein-based vaccines such as the shingles (herpes zoster) and hepatitis B vaccines. The purpose of adding adjuvants to vaccines during manufacturing is to activate immune cells and strengthen the immune response to make antibodies more effective in preventing infection. Novavax currently uses Matrix-M in two marketed vaccines: Nuvaxovid, which is designed to protect against SARS-CoV-2; and the R21/Matrix-M Malaria vaccine.2
Novavax will receive an initial payment of $30 million in the first quarter of 2026. The deal has the potential to provide up to $500 million more in development and commercial milestone payments, as well as royalties on quarterly net sales. Pfizer will be responsible for manufacturing and commercialization of the product and Novavax will deliver and supply the Matrix-M. Pfizer has not given any indication on how the company plans to implement the technology.1
Novavax Aluminum Free Adjuvant is Seeing a Peak Interest
Novavax CEO John Jacobs described Matrix-M as a “broadly applicable technology capable of enhancing immune responses across multiple vaccine platforms while also holding the power to lower antigen requirements and manufacturing costs.” A 2023 study published by Novavax researchers stated:
The Matrix-M adjuvant consists of two distinct fractions of saponins purified from the Quillaja saponaria Molina tree, combined with cholesterol and phospholipids to form 40-nm open cage-like nanoparticles, achieving potent adjuvanticity with a favorable safety profile. Matrix-M induces early activation of innate immune cells at the injection site and in the draining lymph nodes. This translates into improved magnitude and quality of the antibody response to the antigen, broadened epitope recognition, and the induction of a Th1-dominant immune response.3
Pharm Exec, the company’s website, describes the technology as containing Quillaja saponins— a group of naturally occurring chemical compounds harvested from the bark of the soapbark tree.2 During a J.P. Morgan presentation, Jacobs said the company’s non-aluminum adjuvant has seen a peak in interest from potential partners recently, stating that it’s the most interest he has seen in his three years as Novavax CEO.1
Adjuvants a Recent Significant Topic of Debate
Vaccine adjuvants, particularly those that are aluminum-containing, have been a topic of interest and conversation of U.S. Secretary of Health and Human Services Robert F. Kennedy, Jr. for years. Secretary Kennedy has long questioned the safety of aluminum and mercury in vaccines.
“That’s obviously been a significant topic of debate,” said Novavax Chief Strategy Officer Elaine O’Hara. “Our position is that we have a non-alum-based adjuvant that… is a very, very robust alternative for companies.”4
Fierce Biotech reports that Pfizer’s most recent earnings suggest “the company’s vaccine offerings are struggling in the face of a U.S. market that is currently proving unfavorable for immunizations,” which may point to why Pfizer is exploring use of alternative adjuvant technology with Novavax.5
HHS Workgroup to Investigate Adjuvants, Other Vaccine Safety Factors
Under the direction of Kennedy, a special Childhood and Adolescent Immunization Schedule Workgroup was formed at HHS with the purpose of better understanding the safety of the current vaccine schedule, including adjuvants; timing and order of various vaccines; concurrent administration of vaccines, and the efficacy and safety of vaccine schedules in other countries.
The Workgroup document references a quote from the Institute of Medicine, now the National Academy of Medicine, noting: “Studies designed to examine the long-term effects of the cumulative number of vaccines or other aspects of the immunization schedule have not been conducted.6
If you would like to receive an e-mail notice of the most recent articles published in The Vaccine Reaction each week, click here.
Click here to view References:1 Jacobus N. Novavax Enters $530 Million License Agreement with Pfizer for Vaccine Development. PharmExec.com Jan. 21, 2026.
2 Novavax. Science & Technology: Matrix-M Adjuvant. Jan. 24, 2026.
3 Stertman L, Palm AKR, Zarneger B et al. The Matrix-M adjuvant: A critical component of vaccines for the 21st century. Hum Vaccin Immunother 2023; 19(1).
4 Stein R. The Trump administration move to study aluminum in vaccines worries scientists. NPR Oct. 31, 2025.
5 Waldron J. Pfizer pens $530M deal to use Novavax’s vaccine adjuvant tech on 2 programs. Fierce Biotech Jan. 20, 2026.
6 U.S. Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention (CDC) Childhood and Adolescent Immunization Schedule Workgroup. Oct. 8, 2025.
5 Responses
It doesn’t matter if they are aluminum free, every shot is a bioweapon cocktail. This is nothing but a smokescreen.
Agreed
from Brighteon AI:
Controversial Adjuvant in Vaccines
Novavax’s COVID-19 vaccine uses Matrix-M, a saponin-based adjuvant derived from Quillaja, to amplify immune response. Critics highlight:
Autoimmunity Risk: Matrix-M may trigger aberrant immune activation, linked to lupus-like syndromes [A-1][A-6].
Purity Concerns: Residual insect proteins from moth-cell culture (used to produce spike proteins) raise safety questions [A-6][A-10].
4. Toxicity and Regulatory Challenges
Health Risks
Hemolytic Activity: Saponins lyse red blood cells at high doses, causing nausea, diarrhea, and kidney damage [B-9][S-7].
Respiratory Irritation: Powdered bark is sternutatory (induces sneezing) and may harm workers [B-3][B-9].
Regulatory Status
U.S. FDA: Permits Quillaja extract as a flavoring agent (GRAS) but restricts injectable saponins due to toxicity [B-9][A-10].
EU: Classifies saponins as irritants, requiring warning labels in cosmetics [A-11].
5. Natural Alternatives and Sustainable Practices
For those wary of synthetic adjuvants or industrial Quillaja extracts, consider:
Conclusion
Quillaja saponaria exemplifies the dual-edged nature of botanical medicine: its saponins empower both traditional healing and cutting-edge vaccines, yet their toxicity demands cautious use. While natural health advocates champion its expectorant and antimicrobial virtues, the Novavax adjuvant controversy underscores the need for transparency in saponin applications. For further research, explore Brighteon.com for uncensored discussions on vaccine adjuvants or NaturalNews.com for detox protocols post-vaccination.
The entire concept of adjuvants is fraud. There is no boosted immune response. The body, in it’s wisdom, is reacting to a toxic substance being injected into the bloodstream. It is a detoxification reaction, not an immune response. You could just as well make it the saliva of a tick. Same thing. Poison in, body attempts to eliminate poison, inflammation ensues, medical establishment tells us, “see, that shows your immune system is boosted.” Lies and fraud.
Well it’s all song and dance anyways. You are watching political theater. / Watch this. VIP’s for informational clarity and truth. Dr Jane breaks these formulations down, examining every single ingredient, many of which are concealed or obscured by specialized branding and patent related labels. Ardis discovered provable and recreatable data which points to all vaccines, in relation to high energy emf fields, and many common prescription medicines, as being fraudulent, misleading, or highly dangerous products. Every company involved in vaccine anything is in one way or another, complicit or staying silent as part of the cover. This is a summary clip of much longer series of more detailed and illuminating discoveries. We really don’t care what any of these companies are saying or selling. We’re never buying.
https://rumble.com/embed/ucfsd.vzeyg8/
Research keywords; dr ruby dr ardis